Best Supplements for Reduced Inflammation
Ranked by research evidence. Compare 85 supplements across 170 papers from the biomedical literature, with effect direction, evidence strength, and dose range for each.
Top picks by evidence
- Moderate evidence3 studies
Across 3 studies, all reported beneficial effects of Lactobacillus casei PXN 37 on reducing inflammation, with 2 out of 3 showing statistically significant results. The predominant effect size is moderate, with one study showing a small effect limited to a specific subgroup. Evidence is strongest for patients with autoimmune diseases (meta-analysis, n=703), where moderate reductions in IL-6, TNFα, and hs-CRP were observed.
- Low evidence15 studies
Across 13 studies, all 13 reported beneficial effects on reduced inflammation, with most effect sizes rated as moderate and 2 studies showing statistically significant findings. The most-studied populations include children with asthma, patients with chronic kidney disease, and individuals with allergic diseases, although no consistent dose range was reported across studies. Overall, the evidence consistently supports a beneficial direction for Lactobacillus rhamnosus in reducing inflammation, with effect sizes predominantly moderate.
- Low evidence9 studies
Across 9 studies, all 9 reported beneficial effects of Lactobacillus acidophilus L-92 on reducing inflammation, with most effect sizes being small to moderate. The strongest evidence comes from a 2025 meta-analysis (n=3390) showing small reductions in several inflammatory markers in subjects with type 2 diabetes. One RCT reported statistically significant moderate reductions in inflammatory markers (ESR, CRP) in underweight adults.
85 supplements
- LowLactobacillus rhamnosusAcross 13 studies, all 13 reported beneficial effects on reduced inflammation, with most effect sizes rated as moderate and 2 studies showing statistically significant findings. The most-studied populations include children with asthma, patients with chronic kidney disease, and individuals with allergic diseases, although no consistent dose range was reported across studies. Overall, the evidence consistently supports a beneficial direction for Lactobacillus rhamnosus in reducing inflammation, with effect sizes predominantly moderate.15 beneficial15 studies
- LowLactobacillus acidophilus L-92Across 9 studies, all 9 reported beneficial effects of Lactobacillus acidophilus L-92 on reducing inflammation, with most effect sizes being small to moderate. The strongest evidence comes from a 2025 meta-analysis (n=3390) showing small reductions in several inflammatory markers in subjects with type 2 diabetes. One RCT reported statistically significant moderate reductions in inflammatory markers (ESR, CRP) in underweight adults.9 beneficial9 studies
- LowBifidobacterium plantarumAcross 8 studies, 7 reported beneficial effects (primarily moderate-sized) on reducing inflammation, while 1 was neutral. The only statistically significant finding came from a meta-analysis in athletes (n=413) showing a moderate reduction in TNF-α (ES=-0.59, p=0.001). Most evidence is from reviews and animal studies; human data are limited to specific populations.8 beneficial1 neutral9 studies
- LowLactobacillus salivarius UCC118Across 8 studies, all 8 reported beneficial effects of Lactobacillus salivarius UCC118 on reducing inflammation, with effect sizes ranging from small to moderate (3 small, 5 moderate). Three of these findings were statistically significant. The evidence primarily comes from reviews and one RCT; the most robust significant effects were observed in women with gestational diabetes mellitus (small effect on C-reactive protein reduction) and in patients with relapsing-remitting multiple sclerosis (moderate effects on multiple inflammatory markers). No consistent dose range was reported across studies.8 beneficial8 studies
- Very lowLactobacillus brevis SBC8803Across 5 database entries, all 5 report beneficial effects on inflammation, with effect sizes ranging from small to moderate (predominantly moderate). However, only 1 study (a randomized controlled trial) provides statistically significant findings; this study used a different Lactobacillus strain (L. plantarum TWK10) rather than L. brevis SBC8803. The remaining studies are narrative reviews or mechanistic studies on other strains, offering indirect evidence. No studies directly investigated L. brevis SBC8803 for inflammation.8 beneficial8 studies
- LowSaccharomyces cerevisiaeAcross 6 studies, all reported beneficial effects with predominantly moderate effect sizes. Only one small human RCT (n=12) showed significant reduction in inflammatory responses. The evidence is limited by lack of human trials and unreported doses.7 beneficial7 studies
- LowBifidobacterium breve Bb-18Across 4 studies, all 4 reported beneficial effects of Bifidobacterium breve Bb-18 on reducing inflammation, with effect sizes ranging from small to moderate. The strongest evidence comes from a large meta-analysis (n=3390) showing small beneficial effects on inflammatory markers in subjects with type 2 diabetes. However, none of the studies reported statistical significance for this specific supplement-outcome pair, and doses were not reported.4 beneficial4 studies
- LowLactobacillus amylovorusAcross 4 studies on Lactobacillus amylovorus and reduced inflammation, all 4 reported beneficial effects. Effect sizes were mixed (small to moderate), with the highest-quality study (a meta-analysis) showing a small beneficial effect on C-reactive protein (CRP) reduction. No consistent dose range or single population could be identified due to limited and heterogeneous data.4 beneficial4 studies
- Very lowBifidobacterium animalis subsp. lactis BB-12Across 4 studies, all reported beneficial effects of Bifidobacterium animalis subsp. lactis BB-12 on reducing inflammation, with effect sizes ranging from small to moderate. However, none of the findings were statistically significant, and all studies were narrative or systematic reviews (with one preclinical study), limiting the strength of conclusions. No specific dose or population was consistently reported.4 beneficial4 studies
- Very lowLactobacillus rhamnosus GR-1Across 3 studies, all reported moderate beneficial effects of Lactobacillus rhamnosus GR-1 on reducing inflammation, with 2 of 3 studies showing statistically significant findings. Evidence is based primarily on in vitro and animal models, with no human trials available; most studies used cell lines or animal models rather than human participants.4 beneficial4 studies
- ModerateLactobacillus casei PXN 37Across 3 studies, all reported beneficial effects of Lactobacillus casei PXN 37 on reducing inflammation, with 2 out of 3 showing statistically significant results. The predominant effect size is moderate, with one study showing a small effect limited to a specific subgroup. Evidence is strongest for patients with autoimmune diseases (meta-analysis, n=703), where moderate reductions in IL-6, TNFα, and hs-CRP were observed.3 beneficial3 studies
- LowLactobacillus casei rhamnosusAcross 3 review papers, all reported beneficial effects of Lactobacillus casei rhamnosus on reducing inflammation, with effect sizes ranging from small to moderate. Two of the three studies were systematic reviews published in 2026, but none reported statistically significant findings and study durations were not consistently reported. The evidence is limited to small samples and preclinical models, with no consistent dose or form data available.3 beneficial3 studies
- LowLactobacillus acidophilus La-14Across 3 studies, all reported beneficial effects of Lactobacillus acidophilus La-14 on reducing inflammation, with effect sizes ranging from small to moderate. However, no findings reached statistical significance. The most-studied population was women with gestational diabetes mellitus (GDM), and no consistent dose range was reported. One study was an animal model, limiting direct human applicability.3 beneficial3 studies
- LowBifidobacterium lactis Bb-02Across 3 studies, all reported beneficial effects (predominantly small) of Bifidobacterium lactis Bb-02 on reducing inflammation markers such as CRP and TNF-α, with no neutral or harmful findings. The strongest evidence (evidence score 7) comes from a large meta-analysis in subjects with type 2 diabetes (n=3,390), showing small beneficial effects on inflammation. No consistent dose range or study duration was reported across the studies.3 beneficial3 studies